Nanobiotix (NBTX) Competitors $5.26 +0.04 (+0.77%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NBTX vs. NRIX, SANA, LENZ, ZYME, ORIC, NAGE, MENS, SION, REPL, and GHRSShould you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Nurix Therapeutics (NRIX), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry. Nanobiotix vs. Its Competitors Nurix Therapeutics Sana Biotechnology LENZ Therapeutics Zymeworks Oric Pharmaceuticals Niagen Bioscience Jyong Biotech Sionna Therapeutics Replimune Group GH Research Nurix Therapeutics (NASDAQ:NRIX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations. Is NRIX or NBTX more profitable? Nanobiotix has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. Nanobiotix's return on equity of 0.00% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% Nanobiotix N/A N/A N/A Which has more volatility and risk, NRIX or NBTX? Nurix Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Do insiders & institutionals hold more shares of NRIX or NBTX? 38.8% of Nanobiotix shares are owned by institutional investors. 7.4% of Nurix Therapeutics shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has stronger valuation and earnings, NRIX or NBTX? Nanobiotix has lower revenue, but higher earnings than Nurix Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M15.71-$193.57M-$2.61-4.30Nanobiotix$39.18M6.33-$73.73MN/AN/A Does the media prefer NRIX or NBTX? In the previous week, Nurix Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 16 mentions for Nurix Therapeutics and 0 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.87 beat Nurix Therapeutics' score of 0.30 indicating that Nanobiotix is being referred to more favorably in the news media. Company Overall Sentiment Nurix Therapeutics Neutral Nanobiotix Very Positive Do analysts prefer NRIX or NBTX? Nurix Therapeutics presently has a consensus target price of $29.31, suggesting a potential upside of 161.49%. Nanobiotix has a consensus target price of $8.00, suggesting a potential upside of 52.09%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.82Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryNurix Therapeutics beats Nanobiotix on 8 of the 14 factors compared between the two stocks. Get Nanobiotix News Delivered to You Automatically Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBTX vs. The Competition Export to ExcelMetricNanobiotixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$249.81M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E RatioN/A4.4521.0120.09Price / Sales6.33709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book-3.485.008.125.65Net Income-$73.73M$30.99M$3.25B$257.91M7 Day Performance-0.19%1.69%0.97%2.09%1 Month Performance20.09%9.20%7.36%11.13%1 Year Performance-5.23%-1.25%31.31%18.40% Nanobiotix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBTXNanobiotix2.6844 of 5 stars$5.26+0.8%$8.00+52.1%-1.9%$249.81M$39.18M0.00100NRIXNurix Therapeutics2.4806 of 5 stars$12.69+2.0%$29.38+131.5%-44.5%$970.15M$54.55M-4.86300Analyst ForecastAnalyst RevisionSANASana Biotechnology3.2939 of 5 stars$4.22+1.0%$9.17+117.2%-30.3%$951.51MN/A-4.80380Positive NewsGap UpLENZLENZ Therapeutics1.3396 of 5 stars$33.73-2.8%$46.60+38.2%+58.5%$949.37MN/A-19.06110ZYMEZymeworks3.1341 of 5 stars$13.35+0.1%$21.00+57.3%+43.1%$930.27M$93.38M-8.90460News CoverageORICOric Pharmaceuticals4.5055 of 5 stars$10.85-2.3%$18.57+71.2%+9.0%$924.64MN/A-5.8080NAGENiagen Bioscience1.6525 of 5 stars$11.26-0.4%$13.22+17.4%N/A$886.95M$99.60M66.24120MENSJyong BiotechN/A$11.61+16.0%N/AN/A$882.71MN/A0.0031Positive NewsGap UpSIONSionna TherapeuticsN/A$19.94-2.4%$38.50+93.1%N/A$879.75MN/A0.0035REPLReplimune Group4.1427 of 5 stars$11.28+2.8%$20.83+84.7%+17.6%$869.58MN/A-3.67210News CoverageAnalyst ForecastOptions VolumeHigh Trading VolumeGHRSGH Research2.0631 of 5 stars$16.49+3.9%$32.00+94.1%+46.1%$857.94MN/A-20.8710Analyst Revision Related Companies and Tools Related Companies Nurix Therapeutics Competitors Sana Biotechnology Competitors LENZ Therapeutics Competitors Zymeworks Competitors Oric Pharmaceuticals Competitors Niagen Bioscience Competitors Jyong Biotech Competitors Sionna Therapeutics Competitors Replimune Group Competitors GH Research Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBTX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
